11am ET / 8am PT
Failures during the drug development process—most of which happen in phase 2 clinical trials—account for 75% of total research and development expenses, according to the National Academy of Sciences. The ability of biopharma executives to spot likely failures earlier in the development process could not only cut costs, it could also help transform some R&D roadblocks into future successes.
This Fierce webinar will bring together executives with expertise in biopharma discovery, R&D and clinical trial design to discuss the benefits and challenges of the fail-fast strategy. It will include representatives of companies that have implemented such a strategy successfully and can provide advice on what did and did not work.
Catherine Stehman - Breen, M.D. 、Chief Research and Development Officer、Obsidian Therapeutics
Trevor Hallam - Ph.D.、Chief Scientific Officer、Sutro Biopharma
Leah Rodriguez - Senior Manager、Research Solutions
Nina Kjellson-General Partner Canaan